Idogen reaches formal granting of patent in Japan
Idogen AB (”Idogen”) today announces that the Japan Patent Office (“JPO”) has granted the company’s patent application. The patent provides Idogen’s vaccine technology with a broad protection and further strengthens the company’s patent portfolio in an important market.
The Japan Patent Office has now formally granted Idogen’s Patent Application covering induction of IDO for treatment of autoimmune diseases and transplant rejection. The patent, granted with patent number 6063392, belongs to Idogen’s second patent family and broadly covers Idogen’s technology in Japan until 2031. Related patent applications in this family are pending in Canada and the US and received a “Notice of Intention to Grant” in Europe in January 2017. Idogen’s first patent family concerns additional aspects of using zebularine for the treatment of autoimmune diseases and rejection of transplanted organs and is so far granted in Europe.
”The granting of our patent application in Japan is pleasing and a statement representing a considerable strengthening of Idogen’s patent portfolio.”, CEO Lars Hedbys comments.
For additional information about Idogen, please contact:
Lars Hedbys, CEO
Tel: +46 (0)46-275 63 30
This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 7th of February 2017.
Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement.
The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com